The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.
February 2nd 2025
Once-weekly tirzepatide may be an alternative to daily hormone shots in patients with congenital generalized lipodystrophy.
HCPLive Endocrinology's flagship diabetes podcast, hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP
Endocrine Case Report: Cirrhotic with Epigastric Pain
February 23rd 2022The latest case report from Brady Pregerson, MD, features a man in his 60s with a history of diabetes and cirrhosis presenting with 2 weeks of right upper quadrant pain with constipation and 2 days of vomiting. Can you determine the correct diagnosis?
Study Details Causal Effect of Obesity on Diabetic Nephropathy
February 22nd 2022Data from an analysis of more than 150,000 patients suggests increased BMI was associated with more than a 3-fold increase in odds of diabetic nephropathy in patients with type 2 diabetes, but this effect was more apparent in women who experienced a 14-fold increase in odds of diabetic nephropathy.
Tandem Diabetes Receives FDA Clearance for t:connect mobile app
February 21st 2022Announced on Feb. 18, the t:connect mobile app, which pairs with the t:slim X2 insulin pump, is the first-ever FDA-cleared smartphone application capable of initiating insulin delivery on both iOS and Android operating systems, according to Tandem Diabetes Care.
Comparing Cost-Effectiveness of Management Approaches for Severe Obesity in T2D
February 16th 2022An economic evaluation using a microsimulation model comparing Roux-en-Y gastric bypass, sleeve gastrectomy, and medical therapy for severe obesity in patients with type 2 diabetes suggests gastric bypass was the most cost-effective approach.
US FDA Approves Eversense E3 CGM System, Allows Use for Up to 6 Months
February 11th 2022Announced on February 11, the approval for Eversense E3 continuous glucose monitoring system allows access to a CGM system with 6 months of longevity and is expected to be available beginning in the second quarter of 2022.
Gestational Diabetes Raises Long-Term Risk of Multiple Cardiovascular Conditions
February 11th 2022AN analysis of the UK Biobank cohort provides insight into the increased risk of cardiovascular disease associated with gestational diabetes, including a 69% increase in risk of stroke and 42% increase in risk of heart failure later in life.
FDA Approves Omnipod 5 Automated Insulin Delivery System for Type 1 Diabetes in Ages 6 and Older
January 28th 2022Announced on Jan. 28, the Omnipod 5 AID becomes the first tubeless automated insulin delivery system with the ability to integrate with the Dexcom G6 continuous glucose Monitoring System and a compatible smartphone to automatically adjust insulin and protect against glycemic events
Study Raises Alarm Over Risk of Chronic Kidney Disease, Rising Obesity Rates in Type 1 Diabetes
January 26th 2022An analysis of data from more than 135k patients with type 1 and type 2 diabetes indicates the age-adjusted rate of chronic kidney disease was greater in type 1 diabetes and also sheds light on the rising rate of obesity in type 1 diabetes.